Literature DB >> 9672196

Pathomorphological aspects of heparin-induced thrombocytopenia II (HIT-II syndrome).

B Hermanns1, U Janssens, S Handt, L Füzesi.   

Abstract

The therapeutic use of heparin results in thrombocytopenia in 5-30% of patients. In 0.1-1% of patients treated with heparin, the platelet count decreases to between 100 x 10(9)/l and 50 x 10(9)/l and leads to severe synchronous central arterial and venous thrombosis with a mortality of 18-36%. This is known as "white-clot syndrome" or heparin-induced thrombocytopenia II (HIT-II syndrome). Whilst the clinical aspects and the central type of thrombosis in HIT-II syndrome are well documented, the histomorphology and differential diagnosis of thrombosis are not. We report three cases of HIT-II syndrome with thrombosis of the central arteries and veins. The HIT-II thrombi could be differentiated from thrombi of other origins, particularly from mural thrombi. Heparin-induced thrombi were seen on microscopical examination to be like onion skin in structure, and immunohistochemistry showed that they had a markedly reduced content of fibrin and clearly enhanced amounts of IgG and IgM. The layered structure thus implied appositional growth. The thrombi in HIT-II syndrome do not seem to be induced by activation of the coagulation cascade, but by platelet aggregation mediated by anti-platelet antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672196     DOI: 10.1007/s004280050203

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  6 in total

Review 1.  Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.

Authors:  S M Said; J Hahn; E Schleyer; M Müller; G M Fiedler; M Buerke; R Prondzinsky
Journal:  Clin Res Cardiol       Date:  2006-12-08       Impact factor: 5.460

2.  Intra-Arterial Eptifibatide in the Management of Thromboembolism during Endovascular Treatment of Intracranial Aneurysms: Case Series and a Review of the Literature.

Authors:  Pankajavalli Ramakrishnan; Albert J Yoo; James D Rabinov; Christopher S Ogilvy; Joshua A Hirsch; Raul G Nogueira
Journal:  Interv Neurol       Date:  2013-10

3.  [Sinus vein thrombosis. A rare complication of heparin-induced thrombocytopenia type II].

Authors:  S Merz; R Fehr; C Gülke
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

4.  Near fatal stent thrombosis in an aneurysmatic RCX as first manifestation of heparin induced thrombocytopenia (HIT) without thrombocytopenia.

Authors:  Marc Zoller; Iskandar Atmowihardjo; Jeanette Huch; Ines Albrecht; Dirk Habedank
Journal:  BMC Cardiovasc Disord       Date:  2021-12-31       Impact factor: 2.298

5.  Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report.

Authors:  Ryo Kaimori; Haruto Nishida; Tomohisa Uchida; Mari Tamura; Kohji Kuroki; Kumi Murata; Kinta Hatakeyama; Yoshihiko Ikeda; Kisaki Amemiya; Akira Nishizono; Tsutomu Daa; Shinjiro Mori
Journal:  Thromb J       Date:  2022-10-06

6.  Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour.

Authors:  A Busch; S Tschernitz; A Thurner; R Kellersmann; U Lorenz
Journal:  Case Rep Vasc Med       Date:  2013-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.